All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
|
|
- Blaise Sanders
- 6 years ago
- Views:
Transcription
1 ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
2 DISCLOSURE Relevant Financial Relationship(s) None Off Label Usage None 2017 MFMER
3 Objectives ICD for Non-Ischemic Cardiomyopathy Case discussion A patient with narrow QRS: ICD or no ICD, and when? A patient with LBBB: CRT-D or CRT-P? Why the question? Evidence-based discussion Guidelines, emergent data and take home message 2017 MFMER
4 62 Year-Old Woman A 62 year-old woman was admitted to the hospital for evaluation of SOB, PND and orthopnea. She was found to be in heart failure. EKG showed SR 90 bpm, QRSD 104 ms. Echo showed an EF of 26%. Angiogram showed no significant CAD. Work up for cardiomyopathy was unrevealing. She responded to diuretics. Her discharge medications included metoprolol, valsartan, lasix and K supplement She had no signs of heart failure at 3-month follow up. Her functional class was NYHA II. A repeat echo showed the EF was 32% 2011 MFMER 2017 MFMER
5 Would you recommend ICD? 1. Yes 2. No 2017 MFMER
6 Primary SCD in Non-ischemic, LVEF 35% Indications for ICD (guidelines 2012) NYHA I II, III IV Disease Nonischemic* IIB I X * Guidelines: GDMT, exclude reversible transient causes of LV dysfunction (no change in VT guideline 2017) * Optimal GDMT 3-9 months: a CMS rule 2011 MFMER 2017 MFMER
7 DANISH Trial: NICM, EF 35%, NYHA II, III, IVa 1,116 patients eligible for randomization 19 had preexisting CRT 626 had indication for CRT 471 did not have indication for CRT 645 underwent randomization 471 underwent randomization 322 assigned to ICD group 323 assigned to control group 234 assigned to ICD group 237 assigned to control group 8 did not undergo ICD implantation 1 died before implantation 1 had unsuccessful implantation 6 withdrew consent 11 had ICD extracted or deactivated 303 had ICD throughout trial Køber L et al. NEJM 2016; 375: remained without ICD during trial 17 underwent ICD implantation during trial 15 had arrhythmia 2 underwent implantation at physician request 6 did not undergo ICD implantation 1 Had unsuccessful implantation 5 withdrew consent 19 had ICD extracted or deactivated 209 had ICD throughout trial 227 remained without ICD during trial 10 underwent ICD implantation during trial 9 had arrhythmia 1 underwent implantation at physician request 2017 MFMER
8 Cumulative Event Rate DANISH Trial: Time-to-Event Cumulative Event Rate Cumulative Event Rate Death from Any Cause Hazard ratio, 0.87 (95% CI ) P= Cardiovascular Death Hazard ratio, 0.77 (95% CI ) P= Control group ICD group Years ~ 4-5%/yr ~ 2-3 %/yr Sudden Cardiac Death Hazard ratio, 0.50 (95% CI ) P=0.005 Control group ICD group Years Køber L et al. NEJM 2016; 375: Control group 0.0 ICD group Years ~ %/yr 2017 MFMER
9 CMS Announcement: May 30, 2017 Reopening national coverage analysis to reconsider indications for ICDs!! 2017 MFMER
10 Non-ischemic CM DEFINITE, EF < 36%, NYHA I-III, NSVT or PVCs (47% had < 90 days from dx to randomization; excluded reversible causes) Probability of survival ICD group Kadish et al, NEJM 2004 P= Survival (yr) At risk (no.) Standard therapy 2017 MFMER
11 Mortality rate SCD-HeFT: ICD vs. Amio vs. Medical RX EF 35%, NYHA II-III, NICM 48% HR (97.5% CI) P Amiodarone vs placebo 1.06 ( ) 0.53 ICD therapy vs placebo 0.77 ( ) Amiodarone (240 deaths; 5-yr event rate 0.340) ICD therapy (182 deaths; 5-yr event rate 0.289) Placebo (244 deaths; 5-yr event rate 0.36) 0.0 Bardy et al, NEJM Months of follow-up At risk (no.) MFMER
12 NICM Primary SCD Prevention by ICD: Meta-Analysis Total Mortality No. of events No. of events Source (Trial name) Bänsch et al, 2002 (CAT) Køber et al, 2016 (DANISH) Kadish et al, 2004 (DEFINITE) Bardy et al, 2005 (SCD-HeFT) Duration of follow-up (mo) ICD group Control group ICD group Control group HR (95% CI) HR (95% CI) Weight (%) 0.81 ( ) 0.83 ( ) 0.65 ( ) 0.73 ( ) Total Fixed effect model Random-effects model Overall P= ( ) 0.75 ( ) Heterogeneity, I 2 =0%; 2 =0; P= Al-Khatib: JAMA Cardiol 2(6): 685, MFMER
13 64 Year-Old Woman 64 year-old woman has idiopathic DM for 4 years. Despite medical therapy, she now has progressive exertional dyspnea walking 2-3 blocks. Most recent EF was 27%, LVEDD/ESD: 62/52. She has been treated with carvedilol, valsartan, lasix, niacin. She is referred to you for consideration of CRT. EKG is shown, QRSD 144 msec. (Ht 5 1, Wt 96 Kg) 2017 MFMER
14 What Would You Recommend? 1. CRT-P 2. CRT-D 2017 MFMER
15 CRT Indications Class LVEF NYHA class IVCD pattern QRS (ms) Rhythm Disease IA (B) 35% II, III, IVa LBBB 150 Sinus Any IIA 35% II, III, IVa LBBB Sinus Any IIA 35% III, IVa Non LBBB 150 Sinus Any IIA 35% II, III, IVa V pacing or QRS criteria+ rate control AF Any IIA 35% II, III, IVa V pacing >40% NA Sinus Any IIB 30% I LBBB 150 Sinus Ischemia IIB 35% III, IVa Non LBBB Sinus Any IIB 35% II Non LBBB 150 Sinus Any 2012 ACCF/AHA/HRS Focused Update; 2013 ACCF/AHA HF Guidelines 2017 MFMER
16 Outcomes of CRT Trials Improvement in 6 minute walk test, 20% Improvement of O2 consumption, 10 15% Improvement in NYHA functional class - most trials approx points, EF ~ Average decrease in Mn Living with Heart Failure Score of approx 10 points Improvement in 70% of patients Fairly consistent on secondary endpoint of decreased hospitalization for CHF, 35 50% All cause mortality COMPANION: CRT-D, 36% relative reduction (p 0.003) CRT-P, 24% relative reduction (p 0.059) CARE-HF: CRT-P 36% relative reduction (p < 0.002) 2017 MFMER
17 COMPANION (NYHA III, IVa, NICM 44%) Death from Any Cause Event-free survival (%) Pharmacologi c therapy (77 events) CRT-P (131 events, P=0.059) CRT-D (105 events, P=0.003) ,080 Days after randomization No. at risk Pharmacologic therapy CRT-P CRT-D Bristow et al: NEJM, MFMER
18 CRT-D vs CRT-P: All-Cause Mortality Ischemic cardiomyopathy Study or subgroup Log hazard ratio) SE Weight Hazard ratio IV, random, 95% CI Morani % 0.81 (0.50, 1.30) Kutyifa % 0.70 (0.51, 0.97) Looi % 0.66 (0.40, 1.10) Reitan % 0.48 (0.28, 0.82) Witt % 0.74 (0.56, 0.97) Total (95% CI) 100.0% 0.70 (0.59, 0.83) Heterogeneity: Tau 2 =0.00; Chi 2 =2.45, df=4 (P=0.65); I 2 =0% Test for overall effect: Z=4.18 (P< ) Non-ischemic cardiomyopathy Study or subgroup Log hazard ratio) SE Weight Hazard ratio IV, random, 95% CI Morani % 0.56 (0.37, 0.84) Kutyifa % 0.98 (0.73, 1.32) Looi % 0.79 (0.44, 1.43) Reitan % 0.52 (0.22, 1.25) Witt % 0.96 (0.61, 1.51) Total (95% CI) 100.0% 0.79 (0.61, 1.02) Heterogeneity: Tau 2 =0.00; Chi 2 =6.20, df=4 (P=0.18); I 2 =36% Test for overall effect: Z=1.78 (P=0.07) Hazard ratio IV, random, 95% CI Favors CRT-D Favors CRT-P Hazard ratio IV, random, 95% CI Favors CRT-D Favors CRT-P Sérgio et al: J Am Heart Assoc. 2015;4:e doi: MFMER
19 All-Cause Mortality: NICM ICD and CRT-D vs Medical Therapy for Primary SCD Prevention Study HR (95% CI) Weight (%) ICD/CRT-D vs. GDMT CAT 0.83 (0.45, 1.52) 7.92 AMIOVIRT 0.87 (0.31, 2.42) 2.78 DEFINITE 0.65 (0.40, SCD-HeFT 0.73 (0.50, 1.07) COMPANION 0.50 (0.29, 0.88) 9.53 DANISH 0.87 (0.68, 1.12) Subtotal (I 2 =0.0%; P=0.565) 0.77 (0.64, 0.91) CRT-D vs. CRT-P COMPANION 0.50 (0.29, 0.88) DANISH (CRT) 0.91 (0.64, 1.29) Subtotal (I 2 =68.7%; P=0.074) 0.70 (0.39, 1.26) ICD vs. GDMT CAT 0.83 (0.45, 1.52) AMIOVIRT 0.87 (0.31, 2.42) 4.21 DEFINITE 0.65 (0.40, 1.06) SCD-HeFT 0.73 (0.50, 1.07) DANISH (No CRT) 0.83 (0.58, 1.19) Subtotal (I 2 =0.0%; P=0.937) 0.76 (0.62, 0.94) Note: weights are from random effects analysis Golwala et al: Circ 135(2): 201, Favors device Favors no device 2017 MFMER
20 DANISH Trial: Subgroup Analysis, All-Cause Mortality Subgroup Age <59 yr 59 to <68 yr 68 yr Sex Female Male NT-proBNP <1177 pg/ml 1177 pg/ml LV ejection fraction <25% 25% Estimated GFR <73 ml/min/1.73 m 2 73 ml/min/1.73 m 2 NYHA functional class II III IV Heart failure duration <18 mo 18 mo Hypertension No Yes Diabetes No Yes Permanent atrial fibrillation No Yes Cause of heart failure Idiopathic Valvular Hypertension Other Preexisting pacemaker No Yes CRT No Yes Overall ICD Group Control Group no. of events/total no. 17/167 36/173 67/216 22/151 98/405 32/266 57/292 70/264 50/292 75/272 45/283 52/297 68/259 31/254 89/301 78/375 42/181 87/457 33/99 83/421 37/135 90/424 4/20 13/62 13/50 108/500 12/56 58/234 62/322 34/181 50/202 47/177 23/ /404 74/268 88/290 65/242 66/318 80/278 50/280 54/300 77/260 36/277 95/283 87/392 44/167 95/448 36/112 91/447 40/ /425 5/21 12/55 14/59 120/514 11/46 65/237 66/323 Hazard Ratio (95% CI) ICD Better Control Better 0.51 ( ) 0.75 ( ) 1.19 ( ) 1.03 ( ) 0.85 ( ) 0.59 ( ) 0.99 ( ) 0.87 ( ) 0.79 ( ) 0.88 ( ) 0.82 ( ) 0.92 ( ) 0.81 ( ) 0.88 ( ) 0.81 ( ) 0.90 ( ) 0.79 ( ) 0.85 ( ) 0.92 ( ) 0.92 ( ) 0.76 ( ) 0.88 ( ) 0.59 ( ) 0.68 ( ) 1.02 ( ) 0.88 ( ) 0.88 ( ) 0.83 ( ) 0.91 ( ) 0.87 ( ) P Value P Value for Interaction Køber, et al: N Engl J Med; 375:1221, MFMER
21 Annual rate of sudden death (per 100 patient-yr) Trends in the Rate of Sudden Death Across Trial Groups Over Time RALES BEST RALES Slope (per decade), per 100 patient-yr; P=0.02 Population MERIT-HF BEST CIBIS-II Val-HeFT MERIT-HF SCD-HeFT CIBIS-II SCD-HeFT CHARM-Added CHARM-Alternative CHARM-Added CHARM-Alternative GISSI-HF CORONA Control group Experimental-therapy group EMPHASIS-HF PARADIGM-HF Year of randomization N Engl J Med 2017;377: MFMER
22 Take Home Message ICD for NICM: All in the Past? Not yet!! ICD vs. GDMT: CAT, DEFINITE, SCD-HeFT, DANISH Mortality benefit not shown from each trial individually Together, mortality was reduced by 23%, significant CRT-D vs. CRT-P: COMPANION, DANISH, Non-RCT A trend towards mortality reduction in favor of CRT-D Patient population is heterogeneous CRT-D for younger patients, less comorbidity, NYHA II 2017 MFMER
23 ICD in NICM All in the Past? Cedars MFMER
24 ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationICD Guidelines: who benefits from an ICD?
ICD Guidelines: who benefits from an ICD? Matthew Bennett Cardiac Electrophysiologist Vancouver Coastal Health, Device Lead Associate Professor, UBC Matthew.bennett@vch.ca Disclosures I have research collaborations
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationHF and CRT: CRT-P versus CRT-D
HF and CRT: CRT-P versus CRT-D Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia VA Medical Center Philadelphia, PA
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationDevices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine
Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football
More informationCardiac Resynchronization ICD Therapy: What is New?
Cardiac Resynchronization ICD Therapy: What is New? Emile Daoud, MD Section Chief, Cardiac Electrophysiology Professor of Medicine The Ohio State University Normal Activation, Narrow QRS Synchrony Abnormal
More informationLarge RCT s of CRT 2002 to present
Have We Expanded Our Use of CRT for Heart Failure Patients? Sana M. Al-Khatib, MD, MHS Associate Professor of Medicine Electrophysiology Section- Division of Cardiology Duke University Potential Conflicts
More informationICD. Guidelines and Critical Review of Trials. Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011
ICD Guidelines and Critical Review of Trials Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011 Disclosure Relevant Financial Relationship(s) None Off
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More information2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
More informationCardiac Resynchronization Therapy Guidelines and Missing Groups
Cardiac Resynchronization Therapy Guidelines and Missing Groups Frank Pelosi, Jr., MD, FACC, FHRS Director, Cardiac Electrophysiology Fellowship Associate Professor of Medicine University of Michigan Health
More informationTHE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA
THE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA Speakers Bureau: Zoll / Lifecore, Sanofi Aventis, Cardionet Consultant: Boston Scientific, St. Jude Medical, Biotronik,
More informationDéfibrillateur Automa0que Implantable et Dysfonc0on Ventriculaire Gauche Chronique Doit- on implanter un DAI à tous les pa3ents avec FEVG 35%?
Défibrillateur Automa0que Implantable et Dysfonc0on Ventriculaire Gauche Chronique Doit- on implanter un DAI à tous les pa3ents avec FEVG 35%? J-Claude Daubert Emeritus professor University of Rennes 1
More informationThoranis Chantrarat MD
Device Therapy in Heart Failure Thoranis Chantrarat MD 1 Scope of presentation Natural history of heart failure Primary and secondary prevention ICD and its indication CRT and its indication 2 Severity
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationImplantable Cardioverter- Defibrillators (ICDs) for the Prevention of SCD: Appropriate Use in Disclosures
Implantable Cardioverter- Defibrillators (ICDs) for the Prevention of SCD: Appropriate Use in 2015 Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief,
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationIndications for and Prediction of Successful Responses of CRT for Patients with Heart Failure
Indications for and Prediction of Successful Responses of CRT for Patients with Heart Failure Edmund Keung, MD Clinical Chief, Cardiology Section San Francisco VAMC October 25, 2008 Presentation Outline
More informationCRT Vs RV Pacing Benefits
CRT-P & CRT-D Indications According to Guidelines are Guidelines Fully Adopted? Salama H. Omar M.D. Prof. Critical Care Medicine, Cairo University CRT Vs RV Pacing Benefits 1 Benefit of Upgrade CTR-P &
More informationCRT-P or CRT-D From North Alberta to Nairobi
CRT-P or CRT-D From North Alberta to Nairobi Dr Mzee Ngunga Aga Khan University Hospital Nairobi KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web:
More informationArthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J.
Saving Lives and Preventing Heart Failure: The MADIT Family of Trials Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY Update in Electrocardiography
More informationSyncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France
Syncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France Syncope in advanced heart failure: high risk of sudden death N = 491 patients with HF (NYHA III-IV)
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationCardiac resynchronization therapy for heart failure: state of the art
Cardiac resynchronization therapy for heart failure: state of the art Béla Merkely MD, PhD, DSc, FESC, FACC Vice president of the European Society of Cardiology Honorary president of the Hungarian Society
More informationWorkingman s Guide to CRT Indications: Making Sense of the Various Guidelines
Workingman s Guide to CRT Indications: Making Sense of the Various Guidelines Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia
More informationNew Advances in the Diagnosis and Management of Acute and Chronic Heart Failure
New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure Deborah Budge, MD Intermountain Healthcare Heart Failure Cardiologist Objectives: State the updates from the ACC 2013 HF
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationHeart Failure Update. Bibiana Cujec MD May 2015
Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases
More informationComparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationIMPLANTABLE DEVICE THERAPY FOR HEART FAILURE
IMPLANTABLE DEVICE THERAPY FOR HEART FAILURE Nora Goldschlager, M.D. MACP, FACC, FAHA, FHRS Cardiology San Francisco General Hospital UCSF Disclosures: None LEADING CAUSES OF DEATH IN US Sudden cardiac
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationNew Strategies For Treating Patients With Chronic Heart Failure
New Strategies For Treating Patients With Chronic Heart Failure Barry Greenberg MD Professor of Medicine Director, Advanced Heart Failure Treatment Program University of California, San Diego Disclosures
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationEndpoints When Treating VT/VF in Patients with ICDs Programming Wojciech Zareba, MD, PhD
Endpoints When Treating VT/VF in Patients with ICDs Programming Wojciech Zareba, MD, PhD Professor of Cardiology/Medicine Director of the Heart Research Follow Up Program, University of Rochester, Rochester,
More informationMADIT Studies: CRT in the Non-LBBB Patient and Other Findings. Arthur J. Moss, MD
MADIT Studies: CRT in the Non-LBBB Patient and Other Findings Arthur J. Moss, MD University of Rochester Medical Cntr. Rochester, NY 13 th Annual New Frontiers in Heart Failure Rx NYC, NY January 26, 2013
More informationInteresting EP Cases Catheter ablation to treat congestive heart failure (CHF)
Interesting EP Cases Catheter ablation to treat congestive heart failure (CHF) Yiming WU, MD, PhD. Alaska heart and vascular institute. ywu@alaskaheart.com 907-561-3211 19 yo man transferred for out side
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationFibrillazione atriale e scompenso: come interrompere il circolo vizioso.
Alessandria, September 23 th 2017 Fibrillazione atriale e scompenso: come interrompere il circolo vizioso. Professor Fiorenzo Gaita Chief of the Cardiovascular Department Città della Salute e della Scienza
More informationRisk prediction in inherited conditions Laminopathies
Risk prediction in inherited conditions Laminopathies Karim Wahbi Cochin hospital, Paris karim.wahbi@aphp.fr Risk prediction in laminopathies Current approach for risk stratification A new score to predict
More informationChronic. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Michael G. Shlipak, MD, MPH
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationEpidemiology of Symptomatic Heart Failure in the U.S.
William T. Abraham, MD, FACP, FACC, FAHA, FESC Professor of Medicine, Physiology, and Cell Biology Director, Division of Cardiovascular Medicine Deputy Director Davis Heart and Lung Research Institute
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationInterventional solutions for atrial fibrillation in patients with heart failure
Interventional solutions for atrial fibrillation in patients with heart failure Advances in Cardiovascular Arrhythmias Great Innovations in Cardiology Matteo Anselmino, MD PhD Division of Cardiology Department
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationManagement of Syncope in Heart Failure. University of Iowa
Management of Syncope in Heart Failure Brian Olshansky University of Iowa 1 Syncope Transient loss of consciousness, with rapid, usually complete, recovery, with or without prodrome A common, non-specific,
More informationImpact of the African American Heart Failure Trial (A-HeFT): Guideline-based Therapy in Blacks with Heart Failure 2016
Impact of the African American Heart Failure Trial (A-HeFT): Guideline-based Therapy in Blacks with Heart Failure 2016 National Minority Quality forum APRIL 11, 2016 Washington,D.C. Keith C. Ferdinand,
More informationCRT: whom does it benefit?
CRT: whom does it benefit? Francisco Leyva BSH Revalidation and Training 2018 Queen Elizabeth Hospital NICE guidelines for CRT LVEF 35% NYHA class I II III IV QRS
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationThe Role of ACEI and ARBs in AF prevention
The Role of ACEI and ARBs in AF prevention Dr. Sameh Shaheen MD, FESC Prof. of cardiology Ain-Shams university Time course of atrial substrate remodeling in relation to the clinical appearance of AF and
More informationabstract n engl j med 375;13 nejm.org September 29,
The new england journal of medicine established in 1812 September 29, 2016 vol. 375 no. 13 Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure Lars Køber, M.D., D.M.Sc., Jens
More informationRole of Ablation of AF and PVCs in the Management of Heart Failure
Role of Ablation of AF and PVCs in the Management of Heart Failure Cara Pellegrini, MD, FHRS Acting Chief, Cardiology, SF VA Associate Professor of Medicine, UCSF Disclosures I have nothing to disclose
More informationAtrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation
Atrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation ANIL K. BHANDARI, M.D, Director, Electrophysiology and EPS Fellowship Program Good Samaritan Hospital/ Harbor UCLA
More informationHeart Failure Management Update
Heart Failure Management Update Rafique Ahmed, MD, PhD, FACC, FCPS Consultant Cardiac Electrophysiologist Baltimore, Maryland, USA Heart Failure - Definition The situation when the heart is incapable of
More informationImplantable Cardioverter-Defibrillator for Non Ischemic Cardiomyopathy: An Updated Meta-Analysis. Pankaj Arora, MD 2
Implantable Cardioverter-Defibrillator for Non Ischemic Cardiomyopathy: An Updated Meta-Analysis Harsh Golwala, MD 1* ; Navkaranbir Singh Bajaj, MD, MPH 1* ; Garima Arora, MD, MRCP 2 ; Pankaj Arora, MD
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationIt has been shown from meta-analysis of randomized clinical trials that patients with a pre-crt QRS duration (QRSD) >150 ms benefit
Cardiac Resynchronization Therapy may be detrimental in patients with a Very Wide QRSD > 180 ms (VWQRSD) and Right Bundle Branch Block Morphology: Analysis From the Medicare ICD Registry Varun Sundaram
More informationDevice Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx
Device Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx Charles Gottlieb, MD Director of Electrophysiology Abington Memorial Hospital Heart Failure Mortality Mechanism of death
More informationScompenso cardiaco e F A : ruolo della ablazione transcatetere. Prof. Fiorenzo Gaita
Scompenso cardiaco e F A : ruolo della ablazione transcatetere Prof. Fiorenzo Gaita Patients with atrial fibrillation (%) Prevalence of AF in HF Trials 60 50 30% NYHA III-IV NYHA IV 40 NYHA II-III 30 20
More information417 Brazilian Journal of Cardiovascular Surgery REVIEW ARTICLE
REVIEW ARTICLE Effectiveness of Implantation of Cardioverter- Defibrillators Therapy in Patients with Non-Ischemic Heart Failure: an Updated Systematic Review and Meta-Analysis Zhenhua Xing 1, MD; Liang
More informationDevice Therapy for Heart Failure
Device Therapy for Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics St Boniface General Hospital,
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationBeta-blockers in heart failure: evidence put into practice
Beta-blockers in heart failure: evidence put into practice John McMurray Professor of Medical Cardiology, University of Glasgow & Consultant Cardiologist,Western Infirmary, Glasgow, UK Eugene Braunwald
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationWhere Does the Wearable Cardioverter Defibrillator (WCD) Fit In?
Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor of Medicine Director,
More informationGender and cardiac resynchronization therapy. Chairs: David Heaven & Belinda Green. Gender and Cardiac Resynchronisation Therapy
Electrophysiology Gender and cardiac resynchronization therapy Dean Boddington Chairs: David Heaven & Belinda Green Gender and Cardiac Resynchronisation Therapy Dean Boddington Tauranga Hospital 1 Disclosure/Warning
More informationBi-Ventricular pacing after the most recent studies
Seminars of the Hellenic Working Groups February 18th-20 20,, 2010, Thessaloniki, Greece Bi-Ventricular pacing after the most recent studies Maurizio Lunati MD Director EP Lab & Unit Cardiology Dpt. Niguarda
More informationHeart failure. Complex clinical syndrome. Estimated prevalence of ~2.4% (NHANES)
Heart failure Complex clinical syndrome caused by any structural or functional impairment of ventricular filling or ejection of blood Estimated prevalence of ~2.4% (NHANES) Etiology Generally divided into
More informationCardiac Resynchronization Therapy for Heart Failure
Cardiac Resynchronization Therapy for Heart Failure Ventricular Dyssynchrony vs Resynchronization Ventricular Dysynchrony Ventricular Dysynchrony 1 Electrical: Inter- or Intraventricular conduction delays
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationResynchronization/Defibrillation
Resynchronization/Defibrillation for Ambulatory Heart Failure Trial Cardiac Resynchronization Therapy for Mild to Moderate Heart Failure George Wells University of Ottawa Heart Institute Department of
More informationHow do I convert my CRT Non Responder into Responder?
How do I convert my CRT Non Responder into Responder? Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting Boston Scientific, Medtronic
More informationHow Do I Balance Bradycardia with Rate Control in Atrial Fibrillation?
How Do I Balance Bradycardia with Rate Control in Atrial Fibrillation? Thang Nguyen MD FRCPC Assistant Professor Section of Cardiology Department of Internal Medicine University of Manitoba Objectives
More informationSCD-HeFT: The Sudden Cardiac Death in Heart Failure Trial
SCD-HeFT: The Sudden Cardiac Death in Heart Failure Trial Gust H. Bardy Seattle Institute for Cardiac Research Seattle, Washington Disclosures Research grants, speaking fees Medtronic Research grants Wyeth
More informationHeart Failure in Women
Heart Failure in Women Disclosure Professor Sindone has received honoraria, speaker fees, consultancy fees, is a member of advisory boards or has appeared on expert panels for: Professor Andrew Sindone
More information8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)
Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationWomen s Heart Health: Holistic Approaches Throughout the Lifetime - Key Differences in Heart Failure in Women
Women s Heart Health: Holistic Approaches Throughout the Lifetime - Key Differences in Heart Failure in Women C. Noel Bairey Merz MD Medical Director and Barbra Streisand Women s Heart Center Preventive
More informationWho does not need a primary preventive ICD?
Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense
More informationMedical Management of Heart Failure
Medical Management of Heart Failure Louisville Symposium on Heart Disease in Women June 28, 2014 Andrew J. Lenneman, MD Assistant Professor of Medicine University of Louisville Division of Cardiovascular
More informationOutline. Chronic Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center Scientific
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More information